# AA PHARMA EUROPE LIMITED

Report and Accounts

31 March 2014



# AA PHARMA EUROPE LIMITED Report and accounts Contents

	Page
Director's report	1
Profit and loss account	2
Balance sheet	3
Notes to the accounts	4-6

#### **AA PHARMA EUROPE LIMITED**

Registered number:

3030237

**Director's Report** 

The director presents her report and accounts for the year ended 31 March 2014.

#### Principal activities

The company's principal activity during the year continued to be that of consultants to the healthcare sector

#### **Directors**

The following persons served as directors during the year:

M Stratford-Bobbitt

B Bobbitt

#### Director's responsibilities

The director is responsible for preparing the report and accounts in accordance with applicable law and regulations.

Company law requires the director to prepare accounts for each financial year. Under that law the director has elected to prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these accounts, the director is required to:

- select suitable accounting policies and then apply them consistently;
- · make judgements and estimates that are reasonable and prudent;
- prepare the accounts on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable her to ensure that the accounts comply with the Companies Act 2006. She is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

#### Small company provisions

EShnbow

This report has been prepared in accordance with the provisions in Part 15 of the Companies Act 2006 applicable to companies subject to the small companies regime.

This report was approved by the board on 16 September 2014 and signed on its behalf.

M Stratford-Bobbitt

Director

# AA PHARMA EUROPE LIMITED Profit and Loss Account for the year ended 31 March 2014

	Notes	2014 £	2013 £
Turnover		74,679	77,204
Administrative expenses		(67,425)	(54,880)
Operating profit	2	7,254	22,324
Interest receivable		1	2
Profit on ordinary activities before taxation		7,255	22,326
Tax on profit on ordinary activities	3	(1,399)	(4,469)
Profit for the financial year		5,856_	17,857

## AA PHARMA EUROPE LIMITED Balance Sheet as at 31 March 2014

1	Notes		2014 £		2013 £
Current assets Debtors Cash at bank and in hand	5 -	18,727 244 18,971	-	16,637 4,960 21,597	
Creditors: amounts falling due within one year	6	(18,913)		(21,595)	
Net current assets	_		58		2
Net assets			58		2
Capital and reserves Called up share capital Profit and loss account	7 8		2 56		2
Shareholders' funds			58	_	2

The director is satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

Members have not required the company to obtain an audit in accordance with section 476 of the Act.

The director acknowledges her responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The accounts have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006 applicable to companies subject to the small companies regime and with the Financial Reporting Standard for Smaller Entities (effective April 2008).

M Stratford-Robbitt

Director

Approved by the board on 16 September 2014

# AA PHARMA EUROPE LIMITED **Notes to the Accounts**

#### for the year ended 31 March 2014

#### Accounting policies

#### Basis of preparation

The accounts have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008).

Turnover represents the amount of services sold net of Value Added Tax. All the turnover and pre-tax profit is generated in the UK from the principal activity of the business.

Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives.

Office Equipment

20% straight line

#### Pensions

The company operates a defined contribution pension scheme. Contributions are charged to the profit and loss account as they become payable in accordance with the rules of the scheme. There are no contribution outstanding or repaid at the balance sheet date.

2	Operating profit	2014 £	2013 £
	This is stated after charging:		
	Directors' remuneration Pension costs	7,000 17,000	7,000 6,500
٠	Number of directors to whom benefits accrued under money purchase pension schemes	1	1_
3	Taxation	2014 £	2013 £
	UK corporation tax	1,399_	4,469
4	Tangible fixed assets		Office Equipme £
	Cost At 1 April 2013		12,801
	At 31 March 2014		12,801
	Depreciation At 1 April 2013	•	12,801
	At 31 March 2014		12,801
	Net book value At 31 March 2014		

# AA PHARMA EUROPE LIMITED Notes to the Accounts for the year ended 31 March 2014

5	Debtors			2014 £	2013 £
	Trade debtors Other debtors			9,015 9,712 18,727	8,027 8,610 16,637
6	Creditors: amounts falling due within one yea	ır		2014 £	2013 £
	Corporation tax Other taxes and social security costs Other creditors			1,450 14,463 3,000 18,913	4,500 14,095 3,000 21,595
7	Share capital	Nominal value	2014 Number	2014 £	2013 £
	Allotted, called up and fully paid: Ordinary shares	£1 each	2	2	22
8	Profit and loss account			2014 £	
	Profit for the year Dividends			5,856 (5,800)	
	At 31 March 2014			56	
9	Dividends			2014 £	2013 £
	Dividends for which the company became liable Dividends paid	during the year:		5,800	17,857
10	Loans to directors Description and conditions	B/fwd £	Paid £	Repaid £	C/fwd £
	M Stratford-Bobbitt Interest free loan	8,411	32,047	(30,746)	9,712
		8,411	32,047	(30,746)	9,712

# AA PHARMA EUROPE LIMITED Notes to the Accounts for the year ended 31 March 2014

### 11 Related party transactions

#### M Stratford-Bobbitt

Director

Dividends of £5,800 (2013: £17,857) were paid to the director.

### 12 Ultimate controlling party

The ultimate controlling party is M Stratford-Bobbitt.